1. Home
  2. STN vs INCY Comparison

STN vs INCY Comparison

Compare STN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STN
  • INCY
  • Stock Information
  • Founded
  • STN 1954
  • INCY 1991
  • Country
  • STN Canada
  • INCY United States
  • Employees
  • STN N/A
  • INCY N/A
  • Industry
  • STN Military/Government/Technical
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • STN Consumer Discretionary
  • INCY Health Care
  • Exchange
  • STN Nasdaq
  • INCY Nasdaq
  • Market Cap
  • STN 12.0B
  • INCY 13.4B
  • IPO Year
  • STN N/A
  • INCY 1993
  • Fundamental
  • Price
  • STN $109.92
  • INCY $68.72
  • Analyst Decision
  • STN
  • INCY Hold
  • Analyst Count
  • STN 0
  • INCY 20
  • Target Price
  • STN N/A
  • INCY $73.81
  • AVG Volume (30 Days)
  • STN 177.9K
  • INCY 1.9M
  • Earning Date
  • STN 08-13-2025
  • INCY 07-29-2025
  • Dividend Yield
  • STN 0.41%
  • INCY N/A
  • EPS Growth
  • STN 14.85
  • INCY N/A
  • EPS
  • STN 2.34
  • INCY 0.10
  • Revenue
  • STN $4,208,787,002.00
  • INCY $4,413,226,000.00
  • Revenue This Year
  • STN $11.87
  • INCY $13.48
  • Revenue Next Year
  • STN $7.82
  • INCY $10.35
  • P/E Ratio
  • STN $46.52
  • INCY $709.82
  • Revenue Growth
  • STN 16.16
  • INCY 17.13
  • 52 Week Low
  • STN $73.18
  • INCY $53.56
  • 52 Week High
  • STN $110.39
  • INCY $83.95
  • Technical
  • Relative Strength Index (RSI)
  • STN 65.85
  • INCY 54.01
  • Support Level
  • STN $108.44
  • INCY $66.85
  • Resistance Level
  • STN $110.39
  • INCY $70.37
  • Average True Range (ATR)
  • STN 1.34
  • INCY 1.78
  • MACD
  • STN -0.22
  • INCY -0.30
  • Stochastic Oscillator
  • STN 91.50
  • INCY 41.60

About STN Stantec Inc

Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: